EFFICACY AND BENEFICIAL EFFECTS OF SOFOSBUVIR WITH DACLATASVIR ON LIVER FUNCTIONS OF EARLIER TREATMENT FAILURE PATIENTS INFECTED WITH GENOTYPE 3 OF HEPATITIS C VIRUS

EFFICACY AND BENEFICIAL EFFECTS OF SOFOSBUVIR WITH DACLATASVIR ON LIVER FUNCTIONS OF EARLIER TREATMENT FAILURE PATIENTS INFECTED WITH GENOTYPE 3 OF HEPATITIS C VIRUS

Objective: To evaluate the efficacy of sofosbuvir with daclatasvir and its promising effects on liver functions especially in respect to earlier treatment failure patients to frame an appropriate regimen for them. Study Design: A prospective, observational cohort study. Place and Duration of S...

Full description

Bibliographic Details
Main Authors:	Sumetha Yaseen, Kulsoom Farhat, Mahwish Gul, Syeda Urooj Zaidi, Maryam Saqib, Ayman Zafar
Format:	Article
Language:	English
Published:	Army Medical College Rawalpindi 2020-04-01
Series:	Pakistan Armed Forces Medical Journal
Subjects:	chronic hepatitis c daclatasvir genotype 3 sofosbuvir
Online Access:	https://www.pafmj.org/index.php/PAFMJ/article/view/4237/2651

Similar Items

Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial
by: Shafiq Ur Rehman Cheema, et al.
Published: (2019-11-01)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
by: Noha Anwar Hassuna, et al.
Published: (2022-12-01)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
by: Phil McEwan, et al.
Published: (2017-07-01)

The Efficacy of Generic Daclatasvir-Sofosbuvir as Pan-Genotypic Regiment for Hepatitis C Virus (HCV) Infected Patients in Bandung Indonesia
by: Muhammad Begawan Bestari, et al.
Published: (2020-07-01)

Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
by: Inas E L-Khedr Mohamed, et al.
Published: (2021-04-01)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
by: Saima Mushtaq, et al.
Published: (2020-09-01)

Decreased in Liver Fibrosis in Patients with HCV/HIV Coinfection After Treatment with Sofosbuvir/Daclatasvir
by: Andreas Jonathan, et al.
Published: (2020-07-01)

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
by: Mohamed G. Mohamed, et al.
Published: (2021-01-01)

Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study
by: Barnaby Flower, et al.
Published: (2023-01-01)

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
by: Sperl J, et al.
Published: (2017-06-01)

Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment
by: Wafaa M. Ezzat, et al.
Published: (2024-01-01)

Cardiovascular Risk Assessment after Sofosbuvir and Daclatasvir Regimen for Chronic Hepatitis C Virus Infection
by: Kareem Ali Maher, et al.
Published: (2023-05-01)

Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection
by: Ahmed OA, et al.
Published: (2018-03-01)

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
by: Michael Duerr, et al.
Published: (2019-02-01)

Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring
by: Ahmed Mohamed El Missiri, et al.
Published: (2020-07-01)

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms
by: Essam Ezzeldin, et al.
Published: (2020-10-01)

Effect of sofosbuvir plus daclatasvir on virological response and liver function tests as a line of treatment for HCV related cirrhosis (a prospective cohort study)
by: Omaima Mohamed Ali, et al.
Published: (2020-07-01)

Evaluation of left ventricular function after sofosbuvir and daclatasvir regimen for chronic hepatitis C
by: Kareem Ali Maher, et al.
Published: (2023-05-01)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
by: Pol S, et al.
Published: (2016-03-01)

Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure
by: Andreas Walker, et al.
Published: (2017-06-01)

Sofosbuvir and daclatasvir are safe and effective in treatment of recurrent hepatitis C virus in Egyptian patients underwent living donor liver transplantation
by: Osama Aboelfotoh Aly, et al.
Published: (2020-09-01)

TREATMENT OF HCV INFECTION BY A COMBINATION OF SOFOSBUVIR AND DACLATASVIR
by: Y. O. SHULPEKOVA, et al.
Published: (2017-05-01)

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience
by: Tang Q, et al.
Published: (2021-06-01)

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study
by: Phunchai Charatcharoenwitthaya, et al.
Published: (2020-03-01)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
by: L.P. Zanaga, et al.

Direct-acting antivirals sofosbuvir and daclatasvir attenuate carbon tetrachloride-induced liver fibrosis in mice
by: Mayadah M. Abdelsalam, et al.
Published: (2023-03-01)

Rapid Virological Response (RVR) of Daclatasvir and Sofosbuvir Plus Ribavirin in Non-Cirrhotic, Treatment-Naive Patients of Hepatitis C Virus Genotype 3
by: Muhammad Sarfraz, et al.
Published: (2018-12-01)

Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study
by: Stefan Bourgeois, et al.
Published: (2020-01-01)

Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial
by: Mostafa Yakoot, et al.
Published: (2017-07-01)

Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcome
by: Hany Mohammed Ibrahim, et al.
Published: (2022-01-01)

Specific, highly sensitive and simple spectrofluorimetric method for quantification of daclatasvir in HCV human plasma patients and in tablets dosage form
by: Ali Ramadan, et al.
Published: (2019-02-01)

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
by: Irina RUSU, et al.
Published: (2020-03-01)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
by: Melissa J. Barber, et al.
Published: (2020-09-01)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
by: Mir F, et al.
Published: (2017-02-01)

Multivariate optimization and evaluation of quaternary mixture in bulk and co-formulated dosage forms by central composite design
by: Rama Tulasi Jampana, et al.
Published: (2021-05-01)

Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
by: Iandra Holzmann, et al.

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
by: Jae Young Oh, et al.
Published: (2019-07-01)

Safety and efficacy of combination therapy (Simeprevir/Sofosbuvir) in the treatment of chronic HCV genotype IV patients
by: Engy A. Wahsh, et al.
Published: (2018-03-01)

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
by: Andrew Hill, et al.
Published: (2017-10-01)

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
by: Mohammed A Babatin, et al.
Published: (2019-01-01)